Open AccessPharmacoeconomic aspects of treatment of psoriasis with biological drugs
Author(s) -
А. В. Рудакова,
А. А. Кубанов
Publication year - 2012
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/vdv663
Subject(s) - ustekinumab , adalimumab , medicine , etanercept , psoriasis , infliximab , psoriasis area and severity index , dermatology life quality index , quality of life (healthcare) , placebo , clinical trial , randomized controlled trial , clinical efficacy , dermatology , physical therapy , disease , alternative medicine , tumor necrosis factor alpha , nursing , pathology
Psoriasis is an autoimmune skin disease substantially reducing the patients’ quality of life. Practical application of biologic drugs made it possible to achieve substantial progress in the psoriasis therapy. Goal of the article: comparative evaluation of the efficacy of etanercept, infliximab, adalimumab and ustekinumab costs in psoriatic patients. Methods. The cost efficacy was evaluated based on the results of randomized placebo-controlled studies. The analysis was conducted by the cost/efficiency method from the point of view of the health care system. Reduction in the severity of the disease by the PASI index vs. baseline was used as a criterion to evaluate the clinical efficacy. The evaluation was carried out for a course of therapy lasting for 52 weeks; the analysis took into consideration data on all patients (both responding and not responding to the treatment in 12 weeks) as well as patients failing to respond to the treatment in 12 weeks and withdrawing from the therapy. Costs and clinical efficacy were assessed for the time period equal to one year. The costs per one patient achieving PASI 75 were taken as the cost/efficacy coefficient. Results: treatment with adalimumab was shown to be characterized by a lower cost/efficacy coefficient vs. etanercept; infliximab or ustekinumab. Withdrawal in case of non-responding patients in 12 weeks reduces the therapy costs by 17%—40%. In this case, adalimumab proves to be more cost efficient. Conclusions. Treatment of psoriatic patients with adalimumab is expedient from the clinical and economic points of view since it is characterized by the minimum cost/efficacy ratio against the background of high clinical efficacy vs. etanercept; infliximab or ustekinumab.